Drug Trial Radar · NCT02053610
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
Last checked: Nov 19, 2026Latest source record: Sep 14, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
787
Actual
Start
Dec 31, 2009
Primary completion
Aug 31, 2013
Study completion Aug 23, 2017
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- German CLL Study Group; Genentech, Inc.
- First posted
- Feb 3, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This open-label, randomized, 3-arm study will evaluate the efficacy and safety of (obinutuzumab) RO5072759 in combination with chlorambucil as compared to rituximab plus chlorambucil or chlorambucil alone in patients with previously untreated chronic lymphocytic leukemia (CLL). Patients will be randomized 2:2:1 to receive a maximum of six 28-day cycles of either RO5072759 (1000 mg intravenous (iv) infusion, on days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) plus chlorambucil (0.5 mg/kg orally, days 1 and 15 of cycles 1-6), or rituximab (iv infusion day 1, 375 mg/m\^2 cycle 1, 500 mg/m\^2 cycles 2-6) plus chlorambucil, or chlorambucil alone. Anticipated time on study treatment is \>6 months and follow-up for disease-progression and safety will be at least 5 years. In the US, this trial is sponsored/managed by Genentech.
Conditions
- Lymphocytic Leukemia, Chronic
Interventions
obinutuzumabDrug
1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 \[first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment\], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
rituximabDrug
375 mg/m\^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m\^2 IV infusions on Day 1 of Cycles 2-6.
chlorambucilDrug
Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Randomization to clinical cutoff (median observation 59.4 months)
- Percentage of Participants With Progression Free Survival EventsTime frame: Randomization to clinical cutoff (median observation 59.4 months)
Locations
261 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
San Diego, California
Site not named
Chicago, Illinois
Site not named
Baltimore, Maryland
Site not named
Green Bay, Wisconsin
Site not named
Waukesha, Wisconsin
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Buenos Aires, Argentina
Site not named
Rosario, Argentina
Site not named
Adelaide, New South Wales, Australia
Site not named
Gosford, New South Wales, Australia
Site not named
Kogarah, New South Wales, Australia
Site not named
Liverpool, New South Wales, Australia
Site not named
St Leonards, New South Wales, Australia
Site not named
Sydney, New South Wales, Australia
Site not named
Greenslopes, Queensland, Australia
Site not named
Southport, Queensland, Australia
Site not named
Woolloongabba, Queensland, Australia
Site not named
Kurralta Park, South Australia, Australia
Site not named
Frankston, Victoria, Australia
Site not named
Melbourne, Victoria, Australia
Site not named
Graz, Austria
Site not named
Innsbruck, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Goiânia, Goiás, Brazil
Site not named
Belo Horizonte, Minas Gerais, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
Santo André, São Paulo, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Pleven, Bulgaria
Site not named
Plovdiv, Bulgaria
Site not named
Sofia, Bulgaria
Site not named
Varna, Bulgaria
Site not named
Vratsa, Bulgaria
Site not named
Calgary, Alberta, Canada
Site not named
Edmonton, Alberta, Canada
Showing 40 of 261 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.